In 2026, both Johnson & Johnson (J&J) and Merck have seen strong stock gains, but J&J's dividend appears more secure for retirement investors. J&J has a consistent history of annual dividend raises, strong free cash flow, and has already faced its major patent expirations. Merck, while offering a higher yield, faces a significant patent cliff ahead, especially with Keytruda representing nearly half its pharma revenue, and carries more debt from recent acquisitions. J&J's balance sheet and diversified product growth give it an edge, making it the preferred choice for stable dividend income moving forward.
Johnson & Johnson (JNJ) trades at USD 260.29 with a dividend yield of 2.02% on Pluang, while Merck (MRK) is priced at USD 144.03 offering a slightly higher yield of 2.34%. Despite Merck's higher yield, Pluang users show more confidence in JNJ, with 79% buy orders compared to 46% for MRK. These figures are as of Oct 01, 2026 23:31 WIB.
Bank of America increased price targets for AbbVie to $289 and Johnson & Johnson to $278, maintaining Buy and Neutral ratings respectively. AbbVie is favored due to its strong growth potential, robust pipeline, and attractive valuation at 16 times fo...
Bank of America raised its peak sales forecast for Johnson & Johnson's oral psoriasis drug Icotyde to $4.5 billion, up from $2.4 billion, reflecting increased market share assumptions and a sector rerating favoring defensive stocks. The broker projec...
Johnson & Johnson will announce its third-quarter results on October 13. The company saw a 6.6% revenue increase in Q2 to $25.31 billion, driven by strong sales in its multiple myeloma portfolio and the drug Tremfya. Recent data suggests a significan...
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
